We reiterate our Accumulate recommendation and EUR 9.10 target price. After a financing agreement made in April 2018 we believe that Hoivatilat has good preconditions to continue growing strongly and profitably as seen in recent years, thanks to the strong demand drivers on the markets. According to our view, the market undervalues the company’s development business and we see clear upside potential in the valuation.
Show your love by gifting this content to a fellow investor. As a Premium subscriber you can gift Premium-content to a free-user friend. Gift link: